Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)

Inclusion Criteria: * Male or female ≥ 18 years of age * Coronary artery disease at high risk (Syntax Score ≥ 33) * Patients had to have a fasting LDL cholesterol level of 1.4 mmol per liter while they had been taken an optimized regimen of lipid-lowering therapy for at least 4 weeks, which was defined as preferably a high intensity statin but must have been at least atorvastatin at a dose of 20 mg daily or its equivalent, with or without ezetimibe. Exclusion Criteria: * New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30% * Uncontrolled hypertension * Uncontrolled or recurrent ventricular tachycardia * Untreated hyperthyroidism or hypothyroidism * Homozygous familial hypercholesterolemia * LDL or plasma apheresis